Review



human her2 female breast cancer cell lines bt474 ts  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    ATCC human her2 female breast cancer cell lines bt474 ts
    Human Her2 Female Breast Cancer Cell Lines Bt474 Ts, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 3929 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human her2 female breast cancer cell lines bt474 ts/product/ATCC
    Average 99 stars, based on 3929 article reviews
    human her2 female breast cancer cell lines bt474 ts - by Bioz Stars, 2026-06
    99/100 stars

    Images



    Similar Products

    human her2 female breast cancer cell lines bt474 ts  (ATCC)
    99
    ATCC human her2 female breast cancer cell lines bt474 ts
    Human Her2 Female Breast Cancer Cell Lines Bt474 Ts, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human her2 female breast cancer cell lines bt474 ts/product/ATCC
    Average 99 stars, based on 1 article reviews
    human her2 female breast cancer cell lines bt474 ts - by Bioz Stars, 2026-06
    99/100 stars
    		  Buy from Supplier
    trastuzumab deruxtecan her2  (Daiichi Sankyo)
    86
    Daiichi Sankyo trastuzumab deruxtecan her2
    Trastuzumab Deruxtecan Her2, supplied by Daiichi Sankyo, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/trastuzumab deruxtecan her2/product/Daiichi Sankyo
    Average 86 stars, based on 1 article reviews
    trastuzumab deruxtecan her2 - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    retrospective her2 data  (Databank Inc)
    86
    Databank Inc retrospective her2 data
    Retrospective Her2 Data, supplied by Databank Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/retrospective her2 data/product/Databank Inc
    Average 86 stars, based on 1 article reviews
    retrospective her2 data - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    her2 targeted adcs  (Caris Life Sciences)
    86
    Caris Life Sciences her2 targeted adcs
    Her2 Targeted Adcs, supplied by Caris Life Sciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/her2 targeted adcs/product/Caris Life Sciences
    Average 86 stars, based on 1 article reviews
    her2 targeted adcs - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    her2  (Affibody)
    86
    Affibody her2
    Her2, supplied by Affibody, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/her2/product/Affibody
    Average 86 stars, based on 1 article reviews
    her2 - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    her2  (Galectin Therapeutics)
    86
    Galectin Therapeutics her2
    Immunohistochemical (IHC) staining in control and marked groups. Lung cance ( A ) The immunohistochemical scores of the control group were TTF-1 (3+, 90%), Napsin A (3+, 80%), p53 (2+, 50%), Ki-67 (2+,70%), and PD-L1 (TPS < 1%). The immunohistochemical scores of the nano-TiO₂ group were TTF-1 (2+, 60%), Napsin A (3+, 90%), p53 (2+, 45%), Ki-67 (85%), and PD-L1 (TPS < 1%).TPS, tumor proportion score; Thyroid cancer ( B ) The immunohistochemical scores of the control group were Galectin-3 (3+, 90%), TPO (1+, 3%), CD56 (0), and BRAF V600E (3+, 80%). The immunohistochemical scores of the nano-TiO 2 group were Galectin-3 (2+, 70%), TPO (1+, 5%), CD56 (2+, 10%), and BRAF V600E (3+, 90%); Breast cancer ( C ) The immunohistochemical scores of the control group were ER (2+, 30%), PR (3+, 30%), and <t>HER2</t> (1+). The immunohistochemical scores of the DB group were ER (2+, 80%), PR (3+, 80%), and HER2 (1+) (×200)
    Her2, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/her2/product/Galectin Therapeutics
    Average 86 stars, based on 1 article reviews
    her2 - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    her2 trastuzumab  (Procell Inc)
    86
    Procell Inc her2 trastuzumab
    Immunohistochemical (IHC) staining in control and marked groups. Lung cance ( A ) The immunohistochemical scores of the control group were TTF-1 (3+, 90%), Napsin A (3+, 80%), p53 (2+, 50%), Ki-67 (2+,70%), and PD-L1 (TPS < 1%). The immunohistochemical scores of the nano-TiO₂ group were TTF-1 (2+, 60%), Napsin A (3+, 90%), p53 (2+, 45%), Ki-67 (85%), and PD-L1 (TPS < 1%).TPS, tumor proportion score; Thyroid cancer ( B ) The immunohistochemical scores of the control group were Galectin-3 (3+, 90%), TPO (1+, 3%), CD56 (0), and BRAF V600E (3+, 80%). The immunohistochemical scores of the nano-TiO 2 group were Galectin-3 (2+, 70%), TPO (1+, 5%), CD56 (2+, 10%), and BRAF V600E (3+, 90%); Breast cancer ( C ) The immunohistochemical scores of the control group were ER (2+, 30%), PR (3+, 30%), and <t>HER2</t> (1+). The immunohistochemical scores of the DB group were ER (2+, 80%), PR (3+, 80%), and HER2 (1+) (×200)
    Her2 Trastuzumab, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/her2 trastuzumab/product/Procell Inc
    Average 86 stars, based on 1 article reviews
    her2 trastuzumab - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    her2 recognition  (Affibody)
    86
    Affibody her2 recognition
    Immunohistochemical (IHC) staining in control and marked groups. Lung cance ( A ) The immunohistochemical scores of the control group were TTF-1 (3+, 90%), Napsin A (3+, 80%), p53 (2+, 50%), Ki-67 (2+,70%), and PD-L1 (TPS < 1%). The immunohistochemical scores of the nano-TiO₂ group were TTF-1 (2+, 60%), Napsin A (3+, 90%), p53 (2+, 45%), Ki-67 (85%), and PD-L1 (TPS < 1%).TPS, tumor proportion score; Thyroid cancer ( B ) The immunohistochemical scores of the control group were Galectin-3 (3+, 90%), TPO (1+, 3%), CD56 (0), and BRAF V600E (3+, 80%). The immunohistochemical scores of the nano-TiO 2 group were Galectin-3 (2+, 70%), TPO (1+, 5%), CD56 (2+, 10%), and BRAF V600E (3+, 90%); Breast cancer ( C ) The immunohistochemical scores of the control group were ER (2+, 30%), PR (3+, 30%), and <t>HER2</t> (1+). The immunohistochemical scores of the DB group were ER (2+, 80%), PR (3+, 80%), and HER2 (1+) (×200)
    Her2 Recognition, supplied by Affibody, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/her2 recognition/product/Affibody
    Average 86 stars, based on 1 article reviews
    her2 recognition - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    her2 targeting affibody drug conjugates  (Affibody)
    86
    Affibody her2 targeting affibody drug conjugates
    Immunohistochemical (IHC) staining in control and marked groups. Lung cance ( A ) The immunohistochemical scores of the control group were TTF-1 (3+, 90%), Napsin A (3+, 80%), p53 (2+, 50%), Ki-67 (2+,70%), and PD-L1 (TPS < 1%). The immunohistochemical scores of the nano-TiO₂ group were TTF-1 (2+, 60%), Napsin A (3+, 90%), p53 (2+, 45%), Ki-67 (85%), and PD-L1 (TPS < 1%).TPS, tumor proportion score; Thyroid cancer ( B ) The immunohistochemical scores of the control group were Galectin-3 (3+, 90%), TPO (1+, 3%), CD56 (0), and BRAF V600E (3+, 80%). The immunohistochemical scores of the nano-TiO 2 group were Galectin-3 (2+, 70%), TPO (1+, 5%), CD56 (2+, 10%), and BRAF V600E (3+, 90%); Breast cancer ( C ) The immunohistochemical scores of the control group were ER (2+, 30%), PR (3+, 30%), and <t>HER2</t> (1+). The immunohistochemical scores of the DB group were ER (2+, 80%), PR (3+, 80%), and HER2 (1+) (×200)
    Her2 Targeting Affibody Drug Conjugates, supplied by Affibody, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/her2 targeting affibody drug conjugates/product/Affibody
    Average 86 stars, based on 1 article reviews
    her2 targeting affibody drug conjugates - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Immunohistochemical (IHC) staining in control and marked groups. Lung cance ( A ) The immunohistochemical scores of the control group were TTF-1 (3+, 90%), Napsin A (3+, 80%), p53 (2+, 50%), Ki-67 (2+,70%), and PD-L1 (TPS < 1%). The immunohistochemical scores of the nano-TiO₂ group were TTF-1 (2+, 60%), Napsin A (3+, 90%), p53 (2+, 45%), Ki-67 (85%), and PD-L1 (TPS < 1%).TPS, tumor proportion score; Thyroid cancer ( B ) The immunohistochemical scores of the control group were Galectin-3 (3+, 90%), TPO (1+, 3%), CD56 (0), and BRAF V600E (3+, 80%). The immunohistochemical scores of the nano-TiO 2 group were Galectin-3 (2+, 70%), TPO (1+, 5%), CD56 (2+, 10%), and BRAF V600E (3+, 90%); Breast cancer ( C ) The immunohistochemical scores of the control group were ER (2+, 30%), PR (3+, 30%), and HER2 (1+). The immunohistochemical scores of the DB group were ER (2+, 80%), PR (3+, 80%), and HER2 (1+) (×200)

    Journal: Discover Nano

    Article Title: Nano TiO2 and direct black marking system for precise localization in intraoperative pathological diagnosis of small tumors

    doi: 10.1186/s11671-026-04631-5

    Figure Lengend Snippet: Immunohistochemical (IHC) staining in control and marked groups. Lung cance ( A ) The immunohistochemical scores of the control group were TTF-1 (3+, 90%), Napsin A (3+, 80%), p53 (2+, 50%), Ki-67 (2+,70%), and PD-L1 (TPS < 1%). The immunohistochemical scores of the nano-TiO₂ group were TTF-1 (2+, 60%), Napsin A (3+, 90%), p53 (2+, 45%), Ki-67 (85%), and PD-L1 (TPS < 1%).TPS, tumor proportion score; Thyroid cancer ( B ) The immunohistochemical scores of the control group were Galectin-3 (3+, 90%), TPO (1+, 3%), CD56 (0), and BRAF V600E (3+, 80%). The immunohistochemical scores of the nano-TiO 2 group were Galectin-3 (2+, 70%), TPO (1+, 5%), CD56 (2+, 10%), and BRAF V600E (3+, 90%); Breast cancer ( C ) The immunohistochemical scores of the control group were ER (2+, 30%), PR (3+, 30%), and HER2 (1+). The immunohistochemical scores of the DB group were ER (2+, 80%), PR (3+, 80%), and HER2 (1+) (×200)

    Article Snippet: The immunohistochemical scores of the nano-TiO 2 group were Galectin-3 (2+, 70%), TPO (1+, 5%), CD56 (2+, 10%), and BRAF V600E (3+, 90%); Breast cancer ( C ) The immunohistochemical scores of the control group were ER (2+, 30%), PR (3+, 30%), and HER2 (1+).

    Techniques: Immunohistochemical staining, Immunohistochemistry, Control